KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-cash Items (2018 - 2020)

Esperion Therapeutics (ESPR) has disclosed Non-cash Items for 3 consecutive years, with $3.2 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Non-cash Items fell 95.9% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Jun 2020, down 95.9%, and an annual FY2019 reading of $3.0 million, down 96.41% over the prior year.
  • Non-cash Items was $3.2 million for Q2 2020 at Esperion Therapeutics, down from $31.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $173.1 million in Q1 2018 and bottomed at $2.7 million in Q3 2018.
  • Average Non-cash Items over 3 years is $61.0 million, with a median of $63.3 million recorded in 2018.
  • The sharpest move saw Non-cash Items surged 30.65% in 2019, then plummeted 95.9% in 2020.
  • Year by year, Non-cash Items stood at $83.5 million in 2018, then surged by 30.65% to $109.1 million in 2019, then crashed by 97.07% to $3.2 million in 2020.
  • Business Quant data shows Non-cash Items for ESPR at $3.2 million in Q2 2020, $31.1 million in Q1 2020, and $109.1 million in Q4 2019.